Bilateral methicillin-resistant Staphylococcus aureus keratitis after photorefractive keratectomy.
A 52-year-old woman with a history of liver transplantation developed bilateral corneal infiltrates 1 week after uneventful photorefractive keratectomy (PRK). Cultures grew methicillin-resistant Staphylococcus aureus (MRSA), resistant to fluoroquinolone antibiotics. The infections responded to topical vancomycin and resolved bilaterally over 3 weeks. Three months postoperatively, the uncorrected visual acuity (UCVA) was 20/20 in the right eye and 20/25 in the left eye; the best spectacle-corrected visual acuity (BSCVA) was 20/20 in both eyes. During the course of treatment, the patient reported chronic intermittent prophylactic use of oral ciprofloxacin. While fluoroquinolones typically provide excellent postoperative coverage, Staphylococcus organisms have a growing antibiotic resistance to fluoroquinolones, and MRSA may become a more prevalent organism in corneal infections. Chronic subtherapeutic fluoroquinolone use can increase the mutational resistance of Staphylococcus to fluoroquinolone and methicillin. The patient's frequent hospital visits placed her at high risk for MRSA colonization. This case represents the fifth reported case of MRSA keratitis after PRK.
Woodward
Maria
M
Emory University, Department of Ophthalmology and Emory Vision, Atlanta, Georgia, USA. mwoodwa@learnlink.emory.edu
Randleman
J Bradley
JB
D002939:Ciprofloxacin / Q000627:therapeutic use; D015818:Eye Infections, Bacterial / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D005260:Female; D006801:Humans; D007634:Keratitis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D054018:Lasers, Excimer; D016106:Methicillin Resistance; D008875:Middle Aged; D018903:Photorefractive Keratectomy / Q000009:adverse effects*; D013203:Staphylococcal Infections / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D013211:Staphylococcus aureus / Q000187:drug effects / Q000302:isolation & purification*; D014640:Vancomycin / Q000627:therapeutic use
D002939:Ciprofloxacin; D014640:Vancomycin